Russia has given regulatory approval to a second Covid-19 vaccine, named ‘EpiVacCorona’, after early-stage studies. The new coronavirus vaccine comes two months after a similar move for Russia’s first vaccine Sputnik V prompted widespread criticism from scientists both at home and abroad.
Russia became the first country to give regulatory approval to a Covid-19 vaccine in August when Sputnik V was officially registered ahead of the large-scale clinical trial. Russian President Vladimir Putin announced that the country has registered the second Covid-19 vaccine.
- The second Russian vaccine to receive regulatory approval was developed by the Vector State Research Centre of Virology and Biotechnology.
- The two-shot vaccine, ‘EpiVacCorona’, was tested among 100 volunteers in early-stage, placebo-controlled human trials, which lasted more than two months and were completed two weeks ago.
- The volunteers were between 18 and 60 years old.
- Vector’s vaccine EpiVacCorona relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminium-containing adjuvant, according to details posted at ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world.
Important takeaways for all competitive exams:
- Russia President: Vladimir Putin.
- Russia Capital: Moscow.
- Russia Currency: Russian Ruble.